Company

Myovant Sciences Ltd.

Headquarters: London, United Kingdom

Employees: 407

CEO: Mr. David C. Marek

NYSE: MYOV

Market Cap

$2.61 Billion

USD as of Jan. 1, 2023

Market Cap History

Myovant Sciences Ltd. market capitalization over time

Evolution of Myovant Sciences Ltd. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Myovant Sciences Ltd.

Detailed Description

Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. It is also developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility as part of assisted reproduction and is under phase 2 clinical trial. Myovant Sciences Ltd. has collaboration with Pfizer Inc. to develop and commercialize relugolix in oncology and women's health. The company was formerly known as Roivant Endocrinology Ltd. and changed its name to Myovant Sciences Ltd. in May 2016. The company was incorporated in 2016 and is based in London, the United Kingdom. Myovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Myovant Sciences Ltd. has the following listings and related stock indices.


Stock: NYSE: MYOV wb_incandescent

Stock: FSX: 71M wb_incandescent

Details

Headquarters:

11-12 St. James’s Square

Suite 1 3rd Floor

London, SW1Y 4LB

United Kingdom

Phone: 44 20 7400 3351